Denali Therapeutics’ tividenofusp alfa BLA accepted, given Priority Review

Rhea-AI Filing Summary

Denali Therapeutics Inc. (Nasdaq: DNLI) filed a Form 8-K to disclose a material regulatory milestone. On July 7, 2025, the company announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to Denali’s Biologics License Application (BLA) for tividenofusp alfa, its investigational therapy for Hunter syndrome (MPS II). The news was released via a press release attached as Exhibit 99.1. No financial figures, earnings data, or transactions were included in the filing. The Priority Review designation signals that the agency will evaluate the submission under an expedited pathway, underscoring the product’s potential importance for an underserved patient population. Other than routine exhibit listings and signature blocks, the 8-K contains no additional disclosures.

Positive

• FDA acceptance and Priority Review of the tividenofusp alfa BLA materially advances Denali’s Hunter syndrome program and reduces regulatory risk.

Negative

• None.

Insights

Biotechnology Equity Analyst

TL;DR: FDA Priority Review acceptance is a clear positive catalyst for DNLI’s Hunter syndrome program.

The acceptance and Priority Review of the tividenofusp alfa BLA constitutes a significant regulatory advancement. While the filing omits timelines, Priority Review status generally reflects the FDA’s recognition of an unmet medical need and accelerates market-entry prospects. For investors, the milestone de-risks the asset by confirming the completeness of the BLA and initiating a defined review cycle. Given Hunter syndrome’s rare-disease profile, potential approval could yield favorable pricing and orphan-drug exclusivity, enhancing risk-adjusted net present value. The absence of setbacks or additional requests indicates a smooth submission process, which supports a positive outlook.

Regulatory Affairs Specialist

TL;DR: Acceptance signals BLA completeness; Priority Review highlights high-unmet-need status.

The filing confirms two critical points: (1) the BLA met technical filing requirements, avoiding a Refuse-to-File letter, and (2) the FDA assigned Priority Review, implying the agency will allocate extra resources to expedite evaluation. These steps reduce regulatory uncertainty for Denali. Because no FDA objections were noted, the pathway to potential approval is clearer. From a compliance standpoint, Denali properly used Item 7.01 to furnish—rather than file—the information, limiting Exchange Act liability. Overall, the disclosure is straightforward and materially impactful for stakeholders tracking Denali’s pipeline.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001714899FALSE00017148992025-07-072025-07-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

July 7, 2025

Denali Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-38311

46-3872213

(State or other jurisdiction of

(Commission

(I.R.S. Employer

incorporation)

File Number)

Identification No.)

161 Oyster Point Blvd.

South San Francisco, California 94080

(Address of principal executive offices, including zip code)

(650) 866-8547

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last reports)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol (s)			Name of each exchange on which registered
Common Stock, par value $0.01 per share			DNLI			Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company			☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01     Regulation FD Disclosure.

On July 7, 2025, Denali Therapeutics Inc. issued a press release announcing that the U.S. Food and Drug Administration has accepted and granted Priority Review of its Biologics License Application for tividenofusp alfa for the treatment of Hunter syndrome (MPS II).

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information furnished in this Item 7.01 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01     Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press release dated July 7, 2025.
104						Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						DENALI THERAPEUTICS INC.
Date:			July 7, 2025			By:			/s/ Alexander O. Schuth
									Alexander O. Schuth, M.D.
									Chief Operating and Financial Officer

FAQ

What did Denali Therapeutics (DNLI) announce on July 7, 2025?

It reported that the FDA accepted and granted Priority Review to its BLA for tividenofusp alfa for Hunter syndrome.

Which Denali asset received FDA Priority Review?

The investigational biologic tividenofusp alfa for the treatment of Hunter syndrome (MPS II).

Where can investors find the detailed press release?

The press release is attached to the 8-K as Exhibit 99.1 dated July 7, 2025.

What form did Denali use to disclose this information?

Denali filed a Form 8-K under Item 7.01 (Regulation FD Disclosure).

Does the 8-K include any financial results or earnings data?

No. The filing is limited to the regulatory update and accompanying exhibits.